OX1001
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
OX1001 (saquinavir-NO) is an experimental drug being developed by OncoNOx currently undergoing clinical studies and investigations for the treatment of cancer. OX1001 is a nitrate ester analog of the approved HIV protease inhibitor, saquinavir. This modification increases the anti-cancer property while decreasing toxicity of the drug. OX1001 shows broad activity against cancer cells but is particularly effective against hematological, prostate, and melanoma cancers as seen in in vitro and in vivo studies.
OX1001 (saquinavir-NO) is an experimental drug being developed by OncoNOx currently undergoing clinical studies and investigations for the treatment of cancer. OX1001 is a nitrate ester analog of the approved HIV protease inhibitor, saquinavir. This modification increases the anti-cancer property while decreasing toxicity of the drug. OX1001 shows broad activity against cancer cells but is particularly effective against hematological, prostate, and melanoma cancers as seen in in vitro and in vivo studies.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1269859107 under CC BY-SA 4.0; modifications have been made.